Obesity-associated hypertension: Recent progress in deciphering the pathogenesis

Hypertension

Volumn 64, Issue 2, 2014, Pages 215-221

  Rahmouni, Kamal ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOSE TISSUE; ARTICLE; HUMAN; HYPERTENSION; KIDNEY DENERVATION; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; SYMPATHETIC NERVE; SYMPATHETIC TONE; VASCULAR DISEASE;

HUMANS; HYPERTENSION; OBESITY;

EID: 84904468550     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.00920     Document Type: Article

References (78)

1. Jones A, Charakida M, Falaschetti E, Hingorani AD, Finer N, Masi S, Donald AE, Lawlor DA, Smith GD, Deanfield JE. Adipose and height growth through childhood and blood pressure status in a large prospective cohort study. Hypertension. 2012;59:919-925.
2. Suglia SF, Clark CJ, Gary-Webb TL. Adolescent obesity, change in weight status, and hypertension: Racial/ethnic variations. Hypertension. 2013;61:290-295.
3. Tu W, Eckert GJ, DiMeglio LA, Yu Z, Jung J, Pratt JH. Intensified effect of adiposity on blood pressure in overweight and obese children. Hypertension. 2011;58:818-824.
4. Selassie A, Wagner CS, Laken ML, Ferguson ML, Ferdinand KC, Egan BM. Progression is accelerated from prehypertension to hypertension in blacks. Hypertension. 2011;58:579-587.
5. Pausova Z, Mahboubi A, Abrahamowicz M, Leonard GT, Perron M, Richer L, Veillette S, Gaudet D, Paus T. Sex differences in the contributions of visceral and total body fat to blood pressure in adolescence. Hypertension. 2012;59:572-579.
6. Bombelli M, Facchetti R, Sega R, Carugo S, Fodri D, Brambilla G, Giannattasio C, Grassi G, Mancia G. Impact of body mass index and waist circumference on the long-term risk of diabetes mellitus, hypertension, and cardiac organ damage. Hypertension. 2011;58:1029-1035.
7. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: Theory and therapy. Hypertension. 2004;43:518-524.
8. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57:1076-1080.
9. De Ciuceis C, Porteri E, Rizzoni D, Corbellini C, La Boria E, Boari GE, Pilu A, Mittempergher F, Di Betta E, Casella C, Nascimbeni R, Rosei CA, Ruggeri G, Caimi L, Rosei EA. Effects of weight loss on structural and functional alterations of subcutaneous small arteries in obese patients. Hypertension. 2011;58:29-36.
10. Haufe S, Utz W, Engeli S, et al. Left ventricular mass and function with reduced-fat or reduced-carbohydrate hypocaloric diets in overweight and obese subjects. Hypertension. 2012;59:70-75.
11. Weisbrod RM, Shiang T, Al Sayah L, Fry JL, Bajpai S, Reinhart-King CA, Lob HE, Santhanam L, Mitchell G, Cohen RA, Seta F. Arterial stiffening precedes systolic hypertension in diet-induced obesity. Hypertension. 2013;62:1105-1110.
12. Zhang X, Qi Q, Liang J, Hu FB, Sacks FM, Qi L. Neuropeptide Y promoter polymorphism modifies effects of a weight-loss diet on 2-year changes of blood pressure: The preventing overweight using novel dietary strategies trial. Hypertension. 2012;60:1169-1175.
13. Kostis WJ, Cabrera J, Hooper WC, Whelton PK, Espeland MA, Cosgrove NM, Cheng JQ, Deng Y, De Staerck C, Pyle M, Maruthur N, Reyes I, Anderson CA, Liu J, Kostis JB. Relationships between selected gene polymorphisms and blood pressure sensitivity to weight loss in elderly persons with hypertension. Hypertension. 2013;61:857-863.
14. Kokubo Y. Prevention of hypertension and cardiovascular diseases: A comparison of lifestyle factors in westerners and East asians. Hypertension. 2014;63:655-660.
15. Mark AL. Dietary therapy for obesity: An emperor with no clothes. Hypertension. 2008;51:1426-1434; discussion 1434.
16. Julius S, Valentini M, Palatini P. Overweight and hypertension: A 2-way street? Hypertension. 2000;35:807-813.
17. Zhou X, Ma L, Habibi J, Whaley-Connell A, Hayden MR, Tilmon RD, Brown AN, Kim JA, Demarco VG, Sowers JR. Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat. Hypertension. 2010;55:880-888.
18. Jordan J, Engeli S, Boschmann M, Weidinger G, Luft FC, Sharma AM, Kreuzberg U. Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients. J Hypertens. 2005;23:2313-2318.
19. Lambert E, Sari CI, Dawood T, Nguyen J, McGrane M, Eikelis N, Chopra R, Wong C, Chatzivlastou K, Head G, Straznicky N, Esler M, Schlaich M, Lambert G. Sympathetic nervous system activity is associated with obesity-induced subclinical organ damage in young adults. Hypertension. 2010;56:351-358.
20. Armitage JA, Burke SL, Prior LJ, Barzel B, Eikelis N, Lim K, Head GA. Rapid onset of renal sympathetic nerve activation in rabbits fed a high-fat diet. Hypertension. 2012;60:163-171.
21. Muntzel MS, Al-Naimi OA, Barclay A, Ajasin D. Cafeteria diet increases fat mass and chronically elevates lumbar sympathetic nerve activity in rats. Hypertension. 2012;60:1498-1502.
22. Lohmeier TE, Iliescu R, Liu B, Henegar JR, Maric-Bilkan C, Irwin ED. Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension. 2012;59:331-338.
23. Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, Peters T, Sweep FC, Haller H, Pichlmaier AM, Luft FC, Jordan J. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension. 2010;55:619-626.
24. Biaggioni I. Interventional approaches to reduce sympathetic activity in resistant hypertension: To ablate or stimulate? Hypertension. 2012;59:194-195.
25. Lambert GW, Hering D, Esler MD, Marusic P, Lambert EA, Tanamas SK, Shaw J, Krum H, Dixon JB, Barton DA, Schlaich MP. Health-related quality of life after renal denervation in patients with treatment-resistant hypertension. Hypertension. 2012;60:1479-1484.
26. Hering D, Lambert EA, Marusic P, Walton AS, Krum H, Lambert GW, Esler MD, Schlaich MP. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2013;61:457-464.
27. Mahfoud F, Cremers B, Janker J, et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension. 2012;60:419-424.
28. Ewen S, Mahfoud F, Linz D, Pöss J, Cremers B, Kindermann I, Laufs U, Ukena C, Böhm M. Effects of renal sympathetic denervation on exercise blood pressure, heart rate, and capacity in patients with resistant hypertension. Hypertension. 2014;63:839-845.
29. Fadl Elmula FE, Hoffmann P, Fossum E, Brekke M, Gjønnæss E, Hjørnholm U, Kjær VN, Rostrup M, Kjeldsen SE, Os I, Stenehjem AE, Høieggen A. Renal sympathetic denervation in patients with treatmentresistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension. 2013;62:526-532.
30. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393-1401.
31. Hirooka Y, Kishi T, Ito K, Sunagawa K. Potential clinical application of recently discovered brain mechanisms involved in hypertension. Hypertension. 2013;62:995-1002.
32. Hall JE, da Silva AA, do Carmo JM, Dubinion J, Hamza S, Munusamy S, Smith G, Stec DE. Obesity-induced hypertension: Role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem. 2010;285:17271-17276.
33. Harlan SM, Rahmouni K. Neuroanatomical determinants of the sympathetic nerve responses evoked by leptin. Clin Auton Res. 2013;23:1-7.
34. Carlson SH, Wyss JM. Mechanisms underlying hypertension and obesity: A melanocortin linkage in the brain. Hypertension. 2011;57:375-376.
35. Ward KR, Bardgett JF, Wolfgang L, Stocker SD. Sympathetic response to insulin is mediated by melanocortin ? receptors in the hypothalamic paraventricular nucleus. Hypertension. 2011;57:435-441.
36. Greenfield JR, Miller JW, Keogh JM, Henning E, Satterwhite JH, Cameron GS, Astruc B, Mayer JP, Brage S, See TC, Lomas DJ, O'Rahilly S, Farooqi IS. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med. 2009;360:44-52.
37. Sayk F, Heutling D, Dodt C, Iwen KA, Wellhoner JP, Scherag S, Hinney A, Hebebrand J, Lehnert H. Sympathetic function in human carriers of melanocortin-4 receptor gene mutations. J Clin Endocrinol Metab. 2010;95:1998-2002.
38. Purkayastha S, Zhang G, Cai DS. Uncoupling the mechanisms of obesity and hypertension by targeting hypothalamic IKK-beta and NF-kappa B. Nat Med. 2011;17:883-887.
39. do Carmo JM, da Silva AA, Cai Z, Lin S, Dubinion JH, Hall JE. Control of blood pressure, appetite, and glucose by leptin in mice lacking leptin receptors in proopiomelanocortin neurons. Hypertension. 2011;57:918-926.
40. Harlan SM, Morgan DA, Agassandian K, Guo DF, Cassell MD, Sigmund CD, Mark AL, Rahmouni K. Ablation of the leptin receptor in the hypothalamic arcuate nucleus abrogates leptin-induced sympathetic activation. Circ Res. 2011;108:808-812.
41. Dubinion JH, do Carmo JM, Adi A, Hamza S, da Silva AA, Hall JE. Role of proopiomelanocortin neuron Stat3 in regulating arterial pressure and mediating the chronic effects of leptin. Hypertension. 2013;61:1066-1074.
42. Young CN, Morgan DA, Butler SD, Mark AL, Davisson RL. The brain subfornical organ mediates leptin-induced increases in renal sympathetic activity but not its metabolic effects. Hypertension. 2013;61:737-744.
43. Li B, Shi Z, Cassaglia PA, Brooks VL. Leptin acts in the forebrain to differentially influence baroreflex control of lumbar, renal, and splanchnic sympathetic nerve activity and heart rate. Hypertension. 2013;61:812-819.
44. Mark AL. Selective leptin resistance revisited. Am J Physiol Regul Integr Comp Physiol. 2013;305:R566-R581.
45. Machleidt F, Simon P, Krapalis AF, Hallschmid M, Lehnert H, Sayk F. Experimental hyperleptinemia acutely increases vasoconstrictory sympathetic nerve activity in healthy humans. J Clin Endocrinol Metab. 2013;98:E491-E496.
46. Eikelis N, Schlaich M, Aggarwal A, Kaye D, Esler M. Interactions between leptin and the human sympathetic nervous system. Hypertension. 2003;41:1072-1079.
47. Samuelsson AM, Clark J, Rudyk O, Shattock MJ, Bae SE, South T, Pombo J, Redington K, Uppal E, Coen CW, Poston L, Taylor PD. Experimental hyperleptinemia in neonatal rats leads to selective leptin responsiveness, hypertension, and altered myocardial function. Hypertension. 2013;62:627-633.
48. Prior LJ, Davern PJ, Burke SL, Lim K, Armitage JA, Head GA. Exposure to a high-fat diet during development alters leptin and ghrelin sensitivity and elevates renal sympathetic nerve activity and arterial pressure in rabbits. Hypertension. 2014;63:338-345.
49. Rahmouni K. Sympathetic tone in the young: The mother weighs in. Hypertension. 2010;55:21-22.
50. Lim K, Burke SL, Head GA. Obesity-related hypertension and the role of insulin and leptin in high-fat-fed rabbits. Hypertension. 2013;61:628-634.
51. Morgan DA, Rahmouni K. Differential effects of insulin on sympathetic nerve activity in agouti obese mice. J Hypertens. 2010;28:1913-1919.
52. Morgan DA, Thedens DR, Weiss R, Rahmouni K. Mechanisms mediating renal sympathetic activation to leptin in obesity. Am J Physiol Regul Integr Comp Physiol. 2008;295:R1730-R1736.
53. Harlan SM, Morgan DA, Dellsperger DJ, Myers MG Jr, Mark AL, Rahmouni K. Cardiovascular and sympathetic effects of disrupting tyrosine 985 of the leptin receptor. Hypertension. 2011;57:627-632.
54. Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, Corrêa JW, Gagnon AM, Gomez-Sanchez CE, Gomez-Sanchez EP, Sorisky A, Ooi TC, Ruzicka M, Burns KD, Touyz RM. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: Implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension. 2012;59:1069-1078.
55. de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension. 2010;55:147-152.
56. Zavaritskaya O, Zhuravleva N, Schleifenbaum J, Gloe T, Devermann L, Kluge R, Mladenov M, Frey M, Gagov H, Fésüs G, Gollasch M, Schubert R. Role of KCNQ channels in skeletal muscle arteries and periadventitial vascular dysfunction. Hypertension. 2013;61:151-159.
57. Yiannikouris F, Gupte M, Putnam K, Thatcher S, Charnigo R, Rateri DL, Daugherty A, Cassis LA. Adipocyte deficiency of angiotensinogen prevents obesity-induced hypertension in male mice. Hypertension. 2012;60:1524-1530.
58. Grobe JL, Rahmouni K. The adipose/circulating renin-angiotensin system cross-talk enters a new dimension. Hypertension. 2012;60:1389-1390.
59. Park S, Lu KT, Liu X, Chatterjee TK, Rudich SM, Weintraub NL, Kwitek AE, Sigmund CD. Allele-specific expression of angiotensinogen in human subcutaneous adipose tissue. Hypertension. 2013;62:41-47.
60. Xiong XQ, Chen WW, Han Y, Zhou YB, Zhang F, Gao XY, Zhu GQ. Enhanced adipose afferent reflex contributes to sympathetic activation in diet-induced obesity hypertension. Hypertension. 2012;60: 1280-1286.
61. Grubbs V, Lin F, Vittinghoff E, Shlipak MG, Peralta CA, Bansal N, Jacobs DR, Siscovick DS, Lewis CE, Bibbins-Domingo K. Body mass index and early kidney function decline in young adults: A longitudinal analysis of the CARDIA (Coronary Artery Risk Development in Young Adults) Study. Am J Kidney Dis. 2014;63:590-597.
62. Kassab S, Kato T, Wilkins FC, Chen R, Hall JE, Granger JP. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension. 1995;25(4 Pt 2):893-897.
63. Foster MC, Hwang SJ, Porter SA, Massaro JM, Hoffmann U, Fox CS. Fatty kidney, hypertension, and chronic kidney disease: The Framingham Heart Study. Hypertension. 2011;58:784-790.
64. Belin de Chantemele EJ, Ali MI, Mintz JD, Rainey WE, Tremblay ML, Fulton DJ, Stepp DW. Increasing peripheral insulin sensitivity by protein tyrosine phosphatase 1B deletion improves control of blood pressure in obesity. Hypertension. 2012; 60:1273-1279.
65. Beyer AM, Raffai G, Weinberg B, Fredrich K, Lombard JH. Dahl saltsensitive rats are protected against vascular defects related to diet-induced obesity. Hypertension. 2012;60:404-410.
66. Guo DF, Beyer AM, Yang B, Nishimura DY, Sheffield VC, Rahmouni K. Inactivation of Bardet-Biedl syndrome genes causes kidney defects. Am J Physiol Renal Physiol. 2011;300:F574-F580.
67. Bloor ID, Sebert SP, Mahajan RP, Symonds ME. The influence of sex on early stage markers of kidney dysfunction in response to juvenile obesity. Hypertension. 2012;60:991-997.
68. Kennedy DJ, Chen Y, Huang W, Viterna J, Liu J, Westfall K, Tian J, Bartlett DJ, Tang WH, Xie Z, Shapiro JI, Silverstein RL. CD36 and Na/K-ATPase-?iquest;1 form a proinflammatory signaling loop in kidney. Hypertension. 2013;61:216-224.
69. Lurbe E, Torro I, Garcia-Vicent C, Alvarez J, Fernández-Fornoso JA, Redon J. Blood pressure and obesity exert independent influences on pulse wave velocity in youth. Hypertension. 2012;60:550-555.
70. Cao J, Peterson SJ, Sodhi K, Vanella L, Barbagallo I, Rodella LF, Schwartzman ML, Abraham NG, Kappas A. Heme oxygenase gene targeting to adipocytes attenuates adiposity and vascular dysfunction in mice fed a high-fat diet. Hypertension. 2012;60:467-475.
71. Marshall NJ, Liang L, Bodkin J, Dessapt-Baradez C, Nandi M, Collot-Teixeira S, Smillie SJ, Lalgi K, Fernandes ES, Gnudi L, Brain SD. A role for TRPV1 in influencing the onset of cardiovascular disease in obesity. Hypertension. 2013;61:246-252.
72. Beyer AM, Guo DF, Sheffield VC, Rahmouni K. Contrasting vascular effects caused by loss of Bardet-Biedl syndrome genes. Am J Physiol Heart Circ Physiol. 2010;299:H1902-H1907.
73. Beyer AM, Guo DF, Rahmouni K. Prolonged treatment with angiotensin 1-7 improves endothelial function in diet-induced obesity. J Hypertens. 2013;31:730-738.
74. Belin de Chantemele EJ, Mintz JD, Rainey WE, Stepp DW. Impact of leptin-mediated sympatho-activation on cardiovascular function in obese mice. Hypertension. 2011;58:271-279.
75. Leopold JA. Cellular and molecular mechanisms of arterial stiffness associated with obesity. Hypertension. 2013;62:1003-1004.
76. Vandell AG, Lobmeyer MT, Gawronski BE, Langaee TY, Gong Y, Gums JG, Beitelshees AL, Turner ST, Chapman AB, Cooper-DeHoff RM, Bailey KR, Boerwinkle E, Pepine CJ, Liggett SB, Johnson JA. G protein receptor kinase 4 polymorphisms: ?̀-blocker pharmacogenetics and treatmentrelated outcomes in hypertension. Hypertension. 2012;60:957-964.
77. McDonough CW, Gong Y, Padmanabhan S, Burkley B, Langaee TY, Melander O, Pepine CJ, Dominiczak AF, Cooper-Dehoff RM, Johnson JA. Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes. Hypertension. 2013;62:48-54.
78. Campbell CY, Blumenthal RS. Pharmacogenetics of antihypertensive response. Hypertension. 2012;59:1094-1096.